TRCT
VTGN icon

Tower Research Capital (TRC)’s VistaGen Therapeutics VTGN Stock Holding History

Tower Research Capital (TRC)’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.1K Buy
18,136
+16,564
+1,054% +$9.99K ﹤0.01% 4428
2026
Q1 		$898 Sell
1,572
-6,992
-82% -$4.25K ﹤0.01% 4757
2025
Q4 		$5.67K Buy
+8,564
New +$30.9K ﹤0.01% 4105
2025
Q3 		– Sell
-7,721
Closed -$15.4K – 5672
2025
Q2 		$15.4K Buy
+7,721
New +$17.5K ﹤0.01% 3813
2025
Q1 		– Sell
-223
Closed -$658 – 5843
2024
Q4 		$658 Sell
223
-2,036
-90% -$5.73K ﹤0.01% 5209
2024
Q3 		$6.8K Sell
2,259
-225
-9% -$768 ﹤0.01% 4103
2024
Q2 		$8.64K Sell
2,484
-960
-28% -$4.16K ﹤0.01% 4321
2024
Q1 		$18.2K Sell
3,444
-5,854
-63% -$28.1K ﹤0.01% 3081
2023
Q4 		$47.8K Buy
+9,298
New +$35.2K ﹤0.01% 3160
2023
Q2 		– Sell
-3,551
Closed -$13K – 6387
2023
Q1 		$13K Buy
3,551
+785
+28% +$4.12K ﹤0.01% 4018
2022
Q4 		$9K Buy
2,766
+223
+9% +$839 ﹤0.01% 4281
2022
Q3 		$12K Buy
2,543
+1,972
+345% +$19.5K ﹤0.01% 4381
2022
Q2 		$15K Sell
571
-614
-52% -$21.7K ﹤0.01% 4098
2022
Q1 		$44K Buy
1,185
+470
+66% +$20.5K ﹤0.01% 2841
2021
Q4 		$42K Sell
715
-224
-24% -$14.6K ﹤0.01% 2910
2021
Q3 		$78K Buy
939
+889
+1,778% +$77.3K ﹤0.01% 2616
2021
Q2 		$5K Sell
50
-1,436
-97% -$106K ﹤0.01% 4741
2021
Q1 		$95K Buy
+1,486
New +$99.2K ﹤0.01% 2634
2020
Q4 		– Sell
-631
Closed -$13K – 5431
2020
Q3 		$13K Buy
631
+225
+55% +$4.66K ﹤0.01% 4005
2020
Q2 		$6K Buy
+406
New +$5.55K ﹤0.01% 4236
2017
Q3 		– Sell
-19
Closed -$1K – 4171
2017
Q2 		$1K Buy
+19
New +$1.11K ﹤0.01% 2525
2016
Q3 		– Sell
-3
Closed – – 4508
2016
Q2 		$0 Buy
+3
New +$344 ﹤0.01% 5034

Other funds holding VTGN

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CWS
Confluence Wealth Services Mcmurray, Pennsylvania $3.5B AUM 22.08% 1-Year Est. Return

Tower Research Capital (TRC)'s VTGN Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its VistaGen Therapeutics (VTGN) stake by 1,054% in Q2 2026, buying an estimated $9.99K and bringing the position to 18,136 shares worth $4.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4428.

Tower Research Capital (TRC) first reported a position in VTGN in Q2 2016 and has held it in 22 quarters since. The position peaked at $95K in Q1 2021. 26 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Tower Research Capital (TRC) held 18,136 shares of VistaGen Therapeutics worth $4.1K as of Q2 2026.
  • Tower Research Capital (TRC) bought 16,564 VistaGen Therapeutics shares in Q2 2026, an estimated $9.99K.
  • VistaGen Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4428 holding.
  • Tower Research Capital (TRC) first reported a position in VistaGen Therapeutics in Q2 2016 and has held it in 22 quarters since.
  • Tower Research Capital (TRC)'s VistaGen Therapeutics position peaked at $95K in Q1 2021.
  • 26 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.